Table of Contents
<< Previous Issue | Oct 2012 (Vol: 2012, Issue: 10) | Next Issue >> |
- Section: Licensing
-
Roche In-Licenses Galaxy Biotech’s Preclinical FGF2 Antibody Programme
-
Janssen Biotech Licenses Ex-Japan Rights to Astellas’ Oral JAK Inhibitor ASP015K
-
Alfa Wassermann Partners with Theravance to Develop Velusetrag for Gastroparesis
- Section: Mergers & Acquisitions
-
Valeant Expands in Ophthalmology with Acquisition of QLT’s Visudyne ®
-
Sanofi Looks to Second-Generation Emerging Markets with Genfar Acquisition
-
Takeda Boosts Global Vaccine Business with LigoCyte Pharmaceuticals Acquisition
- Section: Research & Development
-
MacroGenics Signs Second Regional Option-Based Deal with Servier
-
Bayer and Evotec Collaborate to Develop Three Endometriosis Drug Candidates
-
Ablynx and Merck & Co. Partner to Develop Nanobody® Ion Channel Modulators
-
Celgene Gains Buyout Option with VentiRx Cancer Collaboration